Skip to main content

Advertisement

SpringerLink
Log in

Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Pancreatic ductal carcinoma is one of the most dismal malignancies of the gastrointestinal system. Even after curative resection, the actual 5-year survival is only 10%–20%. Of all the treatments used against pancreatic cancer, surgery is still the only one that can achieve complete cure. Pancreatic cancer spreads easily to the adjacent tissues and distant metastasis is common. Typically, this cancer invades the retropancreatic neural tissue, duodenum, portal vein (PV), and superior mesenteric vein (SMV), or regional lymph nodes. For this reason, aggressive surgery that removes the cancerous lesion completely is recommended. Several retrospective and prospective studies have been conducted to validate the usefulness of aggressive surgery for pancreatic cancer in the past few decades. Surprisingly, the survival benefits of aggressive surgery have been denied by most randomized controlled trials (RCTs). This implies that surgery alone is not enough. Thus, adjuvant therapy, such as radiotherapy and chemotherapy, has been given in combination with surgery to improve survival. Although the benefits of radiotherapy alone are limited, the results of chemotherapy are promising. Other newly evolving molecular targeting drugs may also improve the treatment outcomes of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385–387.

    Article  PubMed  CAS  Google Scholar 

  3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.

    Article  PubMed  Google Scholar 

  4. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004;198:722–731.

    Article  PubMed  Google Scholar 

  5. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998;227:821–831.

    Article  PubMed  CAS  Google Scholar 

  6. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996;83:625–631.

    Article  PubMed  CAS  Google Scholar 

  7. Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999;29:16–22.

    Article  PubMed  CAS  Google Scholar 

  8. Hayashibe A, Kameyama M, Shinbo M, Makimoto S. The surgical procedure and clinical results of subtotal stomach preserving pancreaticoduodenectomy (SSPPD) in comparison with pylorus preserving pancreaticoduodenectomy (PPPD). J Surg Oncol 2007;95:106–109.

    Article  PubMed  Google Scholar 

  9. Traverso LW, Longmire WP, Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959–962.

    PubMed  CAS  Google Scholar 

  10. Beger HG, Krautzberger W, Bittner R, Buchler M, Limmer J. Duodenum-preserving resection of the head of the pancreas in patients with severe chronic pancreatitis. Surgery 1985;97:467–473.

    PubMed  CAS  Google Scholar 

  11. Hirano S, Kondo S, Ambo Y, Tanaka E, Morikawa T, Okushiba S, Katoh H. Outcome of duodenum-preserving resection of the head of the pancreas for intraductal papillary-mucinous neoplasm. Dig Surg 2004;21:242–245.

    Article  PubMed  Google Scholar 

  12. Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002;137:164–168.

    Article  PubMed  Google Scholar 

  13. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638–645.

    Article  PubMed  CAS  Google Scholar 

  14. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786–795.

    Article  PubMed  CAS  Google Scholar 

  15. Gordon TA, Bowman HM, Tielsch JM, Bass EB, Burleyson GP, Cameron JL. Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg 1998;228:71–78.

    Article  PubMed  CAS  Google Scholar 

  16. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999;126:178–183.

    PubMed  CAS  Google Scholar 

  17. Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. Br J Surg 1997;84:1370–1376.

    Article  PubMed  CAS  Google Scholar 

  18. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–579.

    Article  PubMed  CAS  Google Scholar 

  19. Whipple AO, Parsons WB, Mullins CR. Treatment of Carcinoma of the Ampulla of Vater. Ann Surg 1935;102:763–779.

    Article  PubMed  CAS  Google Scholar 

  20. Braasch JW. Pancreaticoduodenal resection. Curr Probl Surg 1988;25:321–363.

    Article  PubMed  CAS  Google Scholar 

  21. Fink AS, DeSouza LR, Mayer EA, Hawkins R, Longmire WP, Jr. Long-term evaluation of pylorus preservation during pancreaticoduodenectomy. World J Surg 1988;12:663–670.

    Article  PubMed  CAS  Google Scholar 

  22. Kozuschek W, Reith HB, Waleczek H, Haarmann W, Edelmann M, Sonntag D. A comparison of long term results of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy. J Am Coll Surg 1994;178:443–453.

    PubMed  CAS  Google Scholar 

  23. Tsao JI, Rossi RL, Lowell JA. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation. Arch Surg 1994;129:405–412.

    PubMed  CAS  Google Scholar 

  24. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721–31; discussion 731–723.

    Article  PubMed  CAS  Google Scholar 

  25. Klinkenbijl JH, van der Schelling GP, Hop WC, van Pel R, Bruining HA, Jeekel J. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992;216:142–5.

    Article  PubMed  CAS  Google Scholar 

  26. Roder JD, Stein HJ, Huttl W, Siewert JR. Pylorus-preserving versus standard pancreatico-duodenectomy. an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992;79:152–155.

    Article  PubMed  CAS  Google Scholar 

  27. Zerbi A, Balzano G, Patuzzo R, Calori G, Braga M, Di Carlo V. Comparison between pylorus-preserving and Whipple pancreatoduodenectomy. Br J Surg 1995;82:975–979.

    Article  PubMed  CAS  Google Scholar 

  28. Karanicolas PJ, Davies E, Kunz R, Briel M, Koka HP, Payne DM, et al. The pylorus. take it or leave it? Systematic review and metaanalysis of pylorus-preserving versus standard whipple pancreaticoduodenectomy for pancreatic or periampullary cancer. Ann Surg Oncol 2007;14:1825–1834.

    Article  PubMed  Google Scholar 

  29. Paraskevas KI, Avgerinos C, Manes C, Lytras D, Dervenis C. Delayed gastric emptying is associated with pylorus-preserving but not classical Whipple pancreaticoduodenectomy. a review of the literature and critical reappraisal of the implicated pathomechanism. World J Gastroenterol 2006;12:5951–5958.

    PubMed  Google Scholar 

  30. Balcom JHT, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections. changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136:391–398.

    Article  PubMed  Google Scholar 

  31. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995;130:295–299; discussion 299–300.

    PubMed  CAS  Google Scholar 

  32. Sledzianowski JF, Duffas JP, Muscari F, Suc B, Fourtanier F. Risk factors for mortality and intra-abdominal morbidity after distal pancreatectomy. Surgery 2005;137:180–185.

    Article  PubMed  CAS  Google Scholar 

  33. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreatic Cancer Registry in Japan. 20 years of experience. Pancreas 2004;28:219–230.

    Article  PubMed  Google Scholar 

  34. Appleby LH. Removal of the celiac axis in gastrectomy for carcinoma of the stomach in selected cases. a ten-year assessment. J Int Coll Surg 1960;34:143–147.

    PubMed  CAS  Google Scholar 

  35. Hirano S, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer. long-term results. Ann Surg 2007;246:46–51.

    Article  PubMed  Google Scholar 

  36. Yamaguchi K, Nakano K, Kobayashi K, Ogura Y, Konomi H, Sugitani A, et al. Appleby operation for pancreatic body-tail carcinoma. report of three cases. Surg Today 2003;33:873–878.

    Article  PubMed  Google Scholar 

  37. Gagandeep S, Artinyan A, Jabbour N, Mateo R, Matsuoka L, Sher L, et al. Extended pancreatectomy with resection of the celiac axis. the modified Appleby operation. Am J Surg 2006;192:330–335.

    Article  PubMed  Google Scholar 

  38. Kondo S, Katoh H, Hirano S, Ambo Y, Tanaka E, Maeyama Y, et al. Ischemic gastropathy after distal pancreatectomy with celiac axis resection. Surg Today 2004;34:337–340.

    Article  PubMed  Google Scholar 

  39. Kondo S, Katoh H, Shimizu T, Omi M, Hirano S, Ambo Y, et al. Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer. Hepatogastroenterology 2000;47:1447–1449.

    PubMed  CAS  Google Scholar 

  40. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984;199:418–425.

    Article  PubMed  CAS  Google Scholar 

  41. Sindelar WF. Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 1989;124:127–132.

    PubMed  CAS  Google Scholar 

  42. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988;208:215–220.

    Article  PubMed  CAS  Google Scholar 

  43. Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996;77:640–645.

    Article  PubMed  CAS  Google Scholar 

  44. Manabe T, Ohshio G, Baba N, Miyashita T, Asano N, Tamura K, et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989;64:1132–1137.

    Article  PubMed  CAS  Google Scholar 

  45. Mukaiya M, Hirata K, Satoh T, Kimura M, Yamashiro K, Ura H, et al. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas. retrospective multi-institutional analysis in Japan. World J Surg 1998;22:248–252; discussion 252–243.

    Article  PubMed  CAS  Google Scholar 

  46. Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B. Surgery for ductal adenocarcinoma of the pancreatic head. staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000;24:595–601; discussion 601–592.

    Article  PubMed  CAS  Google Scholar 

  47. Gazzaniga GM, Cappato S, Papadia F, Mori L, Filauro M. D1 versus D2 pancreatoduodenectomy in surgical therapy of pancreatic head cancer. Hepatogastroenterology 2001;48:1471–1478.

    PubMed  CAS  Google Scholar 

  48. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508–517.

    Article  PubMed  CAS  Google Scholar 

  49. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2. randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355–366; discussion 366–358.

    Article  PubMed  Google Scholar 

  50. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618–628; discussion 628–630.

    Article  PubMed  Google Scholar 

  51. Nimura Y. Extended surgery in bilio-pancreatic cancer. the Japanese experience. Semin Oncol 2002;29:17–22.

    PubMed  Google Scholar 

  52. Nimura Y. Treatment of pancreatic cancer — surgical point of view (in Japanese). Gan To Kagaku Ryoho 2007;34:993–996.

    PubMed  Google Scholar 

  53. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232–1237.

    Article  PubMed  CAS  Google Scholar 

  54. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52–60.

    Article  PubMed  Google Scholar 

  55. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, et al. Resectable adenocarcinomas in the pancreatic head. the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 2008;8:5.

    Article  PubMed  Google Scholar 

  56. Nakao A, Takeda S, Inoue S, Nomoto S, Kanazumi N, Sugimoto H, et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg 2006;30:976–982; discussion 983–974.

    Article  PubMed  Google Scholar 

  57. Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H. Clinical significance of portal invasion by pancreatic head carcinoma. Surgery 1995;117:50–55.

    Article  PubMed  CAS  Google Scholar 

  58. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996;224:342–347; discussion 347–349.

    Article  PubMed  CAS  Google Scholar 

  59. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998;85:611–617.

    Article  PubMed  CAS  Google Scholar 

  60. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006;10:1106–1115.

    Article  PubMed  Google Scholar 

  61. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006;93:662–673.

    Article  PubMed  CAS  Google Scholar 

  62. Farrell TJ, Barbot DJ, Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann Surg 1997;226:66–69.

    Article  PubMed  CAS  Google Scholar 

  63. Hiraoka T, Kanemitsu K. Value of extended resection and intra-operative radiotherapy for resectable pancreatic cancer. World J Surg 1999;23:930–936.

    Article  PubMed  CAS  Google Scholar 

  64. Zerbi A, Fossati V, Parolini D, Carlucci M, Balzano G, Bordogna G, et al. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994;73:2930–2935.

    Article  PubMed  CAS  Google Scholar 

  65. Di Carlo V, Zerbi A, Balzano G, Villa E. Intraoperative and postoperative radiotherapy in pancreatic cancer. Int J Pancreatol 1997;21:53–58.

    PubMed  Google Scholar 

  66. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.

    PubMed  CAS  Google Scholar 

  67. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–782; discussion 782–774.

    Article  PubMed  CAS  Google Scholar 

  68. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006;244:332–333; author reply 333.

    Article  PubMed  Google Scholar 

  69. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater — results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993;29A:698–703.

    Article  PubMed  CAS  Google Scholar 

  70. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.

    Article  PubMed  CAS  Google Scholar 

  71. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685–1695.

    Article  PubMed  Google Scholar 

  72. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006;36:159–165.

    Article  PubMed  Google Scholar 

  73. Aapro MS, Martin C, Hatty S. Gemcitabine — a safety review. Anticancer Drugs 1998;9:191–201.

    Article  PubMed  CAS  Google Scholar 

  74. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. a randomized trial. J Clin Oncol 1997;15:2403–2413.

    PubMed  CAS  Google Scholar 

  75. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. a randomized controlled trial. JAMA 2007;297:267–277.

    Article  PubMed  CAS  Google Scholar 

  76. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. a randomized controlled trial. JAMA 2008;299:1019–1026.

    Article  PubMed  CAS  Google Scholar 

  77. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.

    Article  PubMed  CAS  Google Scholar 

  78. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007;25:4506–4507; author reply 4508.

    Article  PubMed  Google Scholar 

  79. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer. a multicenter phase II Trial. J Clin Oncol 2004;22:2610–2616.

    Article  PubMed  CAS  Google Scholar 

  80. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  81. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033–8040.

    Article  PubMed  CAS  Google Scholar 

  82. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer. a randomized trial. J Clin Oncol 2001;19:3447–3455.

    PubMed  CAS  Google Scholar 

  83. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161–167.

    Article  PubMed  CAS  Google Scholar 

  84. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas. a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296–3302.

    Article  PubMed  CAS  Google Scholar 

  85. Bloomston M, Zervos EE, Rosemurgy AS 2nd. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668–674.

    Article  PubMed  Google Scholar 

  86. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430–1438.

    Article  PubMed  CAS  Google Scholar 

  87. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma. a North Central Cancer Treatment Group phase II trial. J Clin Oncol 2004;22:4944–4950.

    Article  PubMed  CAS  Google Scholar 

  88. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281–5293.

    Article  PubMed  CAS  Google Scholar 

  89. Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007;52:1964–1972.

    Article  PubMed  CAS  Google Scholar 

  90. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, et al. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007;98:605–611.

    Article  PubMed  CAS  Google Scholar 

  91. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639–1645.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Yukihiro Yokoyama & Masato Nagino

  2. Department of Surgery, Aichi Cancer Center, Nagoya, Japan

    Yuji Nimura

Authors
  1. Yukihiro Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuji Nimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masato Nagino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yokoyama, Y., Nimura, Y. & Nagino, M. Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies. Surg Today 39, 466–475 (2009). https://doi.org/10.1007/s00595-008-3904-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-008-3904-6

Key words

Search

Navigation